Premium
The potential role of ERβ isoforms in the clinical management of breast cancer
Author(s) -
Green C A,
Peter M B,
Speirs V,
Shaaban A M
Publication year - 2008
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2008.02968.x
Subject(s) - gene isoform , breast cancer , medicine , oncology , endocrine system , estrogen receptor , bioinformatics , cancer , cancer research , biology , hormone , gene , genetics
The discovery of a second oestrogen receptor, ERβ, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ERβ isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ERβ isoforms and discusses possible reasons for conflicting results arising from recent research findings.